Bradmer provides clinical trial update and announces evaluation of strategic alternatives
... will be forthcoming. About Glioblastoma multiforme Glioblastoma multiforme (GBM) is the most common and most advanced form ... to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and most advanced form of ...Cancer Mortality Increases With Cancer Cell Replikin Count
... mortality after 5 years. Glioblastoma multiforme and non-small-cell lung cancer, the two cancer ... respectively). The count in Glioblastoma multiforme is 18 times higher than the counts in prostate ... in the laboratory in the case of glioblastoma multiforme brain cancer cells in tissue culture*. The ...Some Immature Brain Cells May Promote Tumors
... used tumor tissue from people with glioblastoma multiforme to develop a cell that ignored the effects of two ... growth. The team then analyzed 54 glioblastoma multiforme tumors and found that one in five (20 percent) ... neuronal stem-like starter cells in glioblastoma multiforme and other cancers, and give us a strong rationale ...Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
... a Phase II trial as a potential new treatment for recurrent glioblastoma multiforme (GBM), a deadly form of brain cancer. The company also reported that ... drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration. A ...NCCN Updates Guidelines for Central Nervous System (CNS) Cancers
... to use bevacizumab as a single agent for recurrent glioblastoma multiforme in CNS cancers, the integration of a patient's Karnofsky Performance ... change in the updated NCCN Guidelines for patients with glioblastoma multiforme is the integration of a patient's Karnofsky Performance Status (KPS) score ...Bradmer to present at Rodman & Renshaw Healthcare Conference
... therapy to the current standard of care for newly diagnosed glioblastoma multiforme (GBM). The presentation will take place on Wednesday, November 12th at ... antibody, conjugated to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and most advanced form of brain cancer. Neuradiab ...JCI online early table of contents: Aug. 1, 2008
... death improves cancer therapy efficacy Individuals with glioblastoma multiforme (GBM), one of the most aggressive types of brain tumor, have an extremely ... to individuals with GBM. TITLE: Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of ...Cytopia Commences Second Phase II Study in Brain Cancer
... Carboplatin and Etoposide in Relapsed Glioblastoma multiforme (CCL08001). Primary endpoints Assess safety and tolerability of ... patients. Subject selection Eligible patients must have glioblastoma multiforme criteria that has progressed after surgery, radiation ...Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
... two previously conducted Phase II trials of Neuradiab(TM) in glioblastoma multiforme (GBM) patients. As an exploratory endpoint of the single arm Phase II ... antibody, conjugated to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and most advanced form of brain cancer. ...Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
... Diagnosed Glioblastoma publication with carmustine multiforme or Anaplastic only. implant) Astrocytoma with ... Gliadel is also indicated in patients with recurrent glioblastoma multiforme as an adjunct to surgery. Gliadel should not be given to individuals who ...UNC study: Scientists identify chemical compound that may stop deadly brain tumors
... gene mutation contributes to tumor growth. The findings and potential treatment apply to a type of brain tumor called secondary glioblastoma multiforme (GBM). GBMs are part of a larger group of brain tumors called malignant gliomas, which is the type of cancer Senator Edward Kennedy suffers from. ...Salk researchers develop novel glioblastoma mouse model
... suspected to be the origin of glioblastoma. Within a few months, massive tumors that displayed all the histological characteristics of glioblastoma multiforme preferentially developed in the hippocampus and the subventricular zone. The ability of adult stem cells to divide and generate both new stem ...Mayo Clinic Cancer Center: Harnessing the measles virus to attack cancer
... and lead researcher on the glioblastoma multiforme project in the measles virus investigation. "We ... seek out this protein, entering the glioblastoma multiforme tumor. Upon entry, the virus begins to spread, ... more potent viral doses." The glioblastoma multiforme study, which opened today, is designed to test ...'Smart drug' targets deadly brain cancer
... categorizes fast-growing glioblastoma multiforme as a grade IV cancer. Significance of the Mayo ... percent) of patients with recurrent glioblastoma multiforme participating in this study -- which is a high ... to target specific changes in the glioblastoma multiforme tumor cells that previous studies have identified ...Investigating the measles virus as a tool to kill multiple myeloma
... being tested today in several tumor types, including glioblastoma multiforme (a brain tumor), recurrent ovarian cancer and now multiple myeloma. ... of higher and potentially even more potent viral doses. The glioblastoma multiforme trial, which opened in the fall, is testing the safety of another strain ...Killing brain tumors from within: A 'Trojan horse' approach
... of epidermal growth factor receptors (EGFR). This proliferation of EGFR is typical of certain types of cancer cells, including glioblastoma multiforme (GBM), the most lethal form of brain cancer. The nucleic acid-EFG molecule acts as a "guided missile," explained Prof. Levitzki, which, when ...Scientist works to improve treatment for brain tumors
... that he developed for the most deadly type of brain tumor. Waldemar Debinski, M.D., Ph.D., pioneered a method to destroy cells of glioblastoma multiforme (GBM) with less damage to healthy cells. The drug is currently being tested in clinical trials and Debinski is working on its fourth generation in ...Radiotherapy advance points way to noninvasive brain cancer treatment
... With an equal rate of incidence and mortality-the number of those who get it, and the number of those who die from it-Glioblastoma multiforme (GBM) is a brain cancer death sentence. Of the approximately 12,000 people who are diagnosed with GBM annually in the U.S., half will die within a ...Preclinical study of a new brain tumor therapy
... the malignant cells. A new preclinical study, published in the open access journal PLoS Medicine, has applied the approach to combat glioblastoma multiforme (GBM). This is the most aggressive form of brain tumour, growing very quickly before symptoms are experienced and killing most patients within a year ...SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
... inhibitor, is cytotoxic to glioblastoma multiforme cell lines (Abstract 178). Activity was also demonstrated in vivo in a glioblastoma multiforme xenograft model. Evidence presented suggests that ... clinical activity of MP470 against glioblastoma multiforme cells is synergistic with radiation. ...Bradmer sponsors physician panel to raise awareness of brain cancer treatments
... days on Bradmer's website. About Glioblastoma Multiforme Glioblastoma multiforme (GBM) is the most common and most advanced form of brain cancer with ... antibody, conjugated to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and most advanced form of brain cancer. Neuradiab ...Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
... with HIV, and two Cotara studies for the treatment of glioblastoma multiforme (GBM), a deadly form of brain cancer. The company reported a ... a clinical update on its Cotara program for the treatment of glioblastoma multiforme (GBM), covering the first cohort of patients in its dosimetry trial as ...Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
... study, which concluded in February 2009. CYT997 is currently undergoing further clinical investigation in Phase II studies in relapsed glioblastoma multiforme and multiple myeloma. Enquiries Dr. Gregg Smith Mr. Andrew Macdonald Director, Drug Development and ...Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR
... 2009, 1:00 pm - 5:00 pm) -- Dual targeting of the receptor tyrosine kinase EGFRvIII and HGF:c-Met signaling in models of glioblastoma multiforme (GBM) Overview: Examined the effect of combining a fully human neutralizing antibody targeting the HGF:c-Met axis (AMG 102), with a ...Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
... when we receive the results of an ongoing 113 patient Phase 2 clinical trial of MGd combined with radiation plus temozolomide in glioblastoma multiforme (GBM). This trial is being conducted by the Radiation Therapy Oncology Group (RTOG) with results expected in late 2010." "Our management team ...SuperGen Reports 2008 Third Quarter Financial Results
... 2008: The Company announced that the FDA granted orphan drug designation for our lead drug candidate, MP-470, for the treatment of glioblastoma multiforme (GBM), an often fatal form of brain cancer. The FDA accepted the Company's application upon review of data from in vitro studies in glioblastoma cell ...